- Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China studyWu, Yi-Long; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Gonzalez Arenas, Carmen; Fu, Wei; Wu, Helen; Mok, TonyAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.被引 1
- Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non-small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).Liu, Si-Yang Maggie; Zhou, Qing; Yan, Hong-Hong; Bin, Gan; Yang, Ming-Yi; Deng, Jia-Yi; Tu, Hai-Yan; Zhang, Xuchao; Su, Jian; Yang, Jinji; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 6
- Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158Mao, Y.; Wu, X.; Xu, N.; Bai, Y.; Wang, D.; Chen, X.; Yin, X.; Deng, Y.; Yang, J.; Zhang, J.; Tang, J.; Huang, Y.; Li, J.; Xu, M.; Li, N.; Mao, Y.; Gozman, A.; Xu, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042
27阅读
